FDA — authorised 12 July 1954
- Marketing authorisation holder: BLULINE
- Status: approved
FDA authorised Antiren on 12 July 1954
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 12 July 1954.
BLULINE holds the US marketing authorisation.